Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.23, read 2026-10-28
Ethical passes the values gate
Price63.39 USD
Fair value96.25
Ethical score74.0/100
RatingOPPORTUNITY
Our investment reviews on this name
2026-10-25Read Markup64.15-1.2% to today Markdown gives way to Markup first Markup read since August
2026-10-11Read Markdown63.06+0.5% to today Distribution gives way to Markdown
2026-10-02Read Distribution63.06+0.5% to today Markup gives way to Distribution after an 8% slide in 5 weeks
2026-08-29Read Markup68.54-7.5% to today Distribution gives way to Markup after a 21% rise in 4 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Fox Corporation (Class A) holds its Markup at $63.39. Consolidating, no directional conviction, held for 26 days.
As held on the ledger · 2026-10-28
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 26 days
Price at the screen
$63.39
Valuation
16.71 trailing · 10.88 forward price to earnings
Values screen
PASS· score 74.0
Beta
0.61
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
32.18%
Below 33%
Interest-bearing debt is just 32.2% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
6.99%
Below 33%
Cash held in interest-bearing accounts and securities is 7.0% of assets, under the one-third limit.
Pass
Receivables
33.73%
Below 49%
Money owed to the company is 33.7% of assets, under the 49% limit.
Pass
Revenue purity
1.08%
Below 5%
Only 1.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Fox Corporation (Class A) clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 32%, inside the ~33% line, and interest is about 1% of its income, under the ~5% line, so it passes.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when FOXA's ethical verdict changes
Today FOXA passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads OPPORTUNITY: it trades at roughly a 52% discount to our $96.25 fair value, moderate competitive moat, 28.10% revenue growth.
Fair value range in USD, drawn from the 2026-10-28 screen. The gold marker is the market price at the same screen. A 51.8% margin of safety to the base estimate.
Third-party analyst targets: 18 covering, consensus Buy. The average target sits +21% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-28 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Fox content machine priced like yesterday's news
Picture the evening news or a Sunday sports package landing in millions of living rooms. Fox still controls those pipes through cable networks and local TV, yet the shares sit at 57 dollars against our fair value of 88, a 53 percent margin of safety on a forward multiple of just 9.9 times. Revenue dipped 9 percent lately but the business still clears an 11 percent profit margin and 15 percent return on equity with a moderate moat intact, and it clears our ethical screen without issue.
Analysts see 70 dollars ahead, yet the valuation gap leaves room even if linear TV keeps shrinking. The combination of cash generative sports rights and news programming creates a durable earnings base that the market appears to be ignoring.
Risk sits with the revenue slide and any deeper advertising pullback if the economy softens further. A moderate moat offers some protection but not immunity from streaming shifts or political ad cycles. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
FOXA trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-28Markup$64.15+0.0%Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (17 analysts) rates it buy, with a mean price target of $74. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Markup$64.15+0.0%Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (17 analysts) rates it buy, with a mean price target of $74. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Markup$64.15+0.0%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (17 analysts) rates it buy, with a mean price target of $74. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markup · changed$64.15+0.0%Entry 9
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (17 analysts) rates it buy, with a mean price target of $74.
2026-10-18Markdown$64.15+1.7%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (17 analysts) rates it buy, with a mean price target of $74.
2026-10-11Markdown · changed$63.06+0.0%Entry 7
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (17 analysts) rates it buy, with a mean price target of $74.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 8.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (17 analysts) rates it buy, with a mean price target of $74.
2026-08-29Markup · changed$68.54+21.0%Entry 5
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 21.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (17 analysts) rates it buy, with a mean price target of $74.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 15.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (17 analysts) rates it buy, with a mean price target of $74.
2026-07-18Markup$66.89+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (17 analysts) rates it buy, with a mean price target of $74.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
